02:01 AM EDT, 08/14/2026 (MT Newswires) -- The European Medicines Agency validated Pfizer (PFE.F) and Valneva's (VLA.PA) marketing authorization application for PF-07307405, the companies' Lyme disease vaccine candidate. The regulator will now start its assessment of the application following validation, according to a Friday release. The application was supported by the late-stage Valor clinical trials, in which the vaccine demonstrated efficacy of more than 70% and was well tolerated. The study evaluated whether PF-07307405 prevented the disease in individuals aged five years and older. The companies are collaborating on developing the 6-valent OspA-based Lyme disease vaccine candidate as part of a deal in April 2020, with Pfizer holding the exclusive rights to manufacture and market the product upon receiving regulatory approvals.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.